Free tool
FAERS Monitor: Kitabis Pak
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 205433 or its brand name (Kitabis Pak, Tobramycin). Reports on generic versions are filed under their own applications.
Reports
13,080
Serious
10,454
80% of reports
Hospitalization
6,400
Death reported
1,288
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use988
- pneumonia838
- infective pulmonary exacerbation of cystic fibrosis710
- dyspnoea708
- drug ineffective696
- acute kidney injury690
- hospitalisation562
- death509
- infection508
- cystic fibrosis495
- cough494
- condition aggravated461
- pyrexia428
- fatigue410
- nausea379
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 80 |
| 2005 | 97 |
| 2006 | 76 |
| 2007 | 124 |
| 2008 | 90 |
| 2009 | 99 |
| 2010 | 101 |
| 2011 | 207 |
| 2012 | 188 |
| 2013 | 164 |
| 2014 | 272 |
| 2015 | 444 |
| 2016 | 513 |
| 2017 | 592 |
| 2018 | 1,110 |
| 2019 | 1,724 |
| 2020 | 1,506 |
| 2021 | 1,081 |
| 2022 | 1,028 |
| 2023 | 866 |
| 2024 | 1,063 |
| 2025 | 933 |
| 2026 | 722 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,041,079 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| infective pulmonary exacerbation of cystic fibrosisSignal | 710 | 241.1 | 223.2 | 147,444 |
| cystic fibrosisSignal | 495 | 157.8 | 144.1 | 70,099 |
| acute kidney injurySignal | 690 | 7.3 | 6.8 | 3,741 |
| hospitalisationSignal | 562 | 5.9 | 5.4 | 2,290 |
| infectionSignal | 508 | 5.7 | 5.2 | 1,951 |
| pneumoniaSignal | 838 | 4.2 | 3.9 | 2,043 |
| coughSignal | 494 | 2.8 | 2.6 | 592 |
| condition aggravatedSignal | 461 | 2.4 | 2.2 | 396 |
| dyspnoeaSignal | 708 | 2.0 | 1.9 | 369 |
| pyrexia | 428 | 2.0 | 1.8 | 213 |
| off label use | 988 | 1.8 | 1.7 | 376 |
| death | 509 | 1.0 | 0.9 | 1 |
| drug ineffective | 696 | 0.8 | 0.8 | 20 |
| fatigue | 410 | 0.8 | 0.8 | 12 |
| nausea | 379 | 0.8 | 0.7 | 27 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.